Cholangiocarcinoma after flow diversion surgery for congenital biliary dilatation: A case report and review of literature

Ryo Ataka, Takashi Ito, Toshihiko Masui, Satoru Seo, Takamichi Ishii, Satoshi Ogiso, Shintaro Yagi, Kojiro Taura, Shinji Uemoto

ORCID number: Ryo Ataka (0000-0002-4314-4034); Takashi Ito (0000-0002-5892-8317); Toshihiko Masui (0000-0002-4001-4824); Satoru Seo (0000-0001-9539-8098); Takamichi Ishii (0000-0002-7461-9653); Satoshi Ogiso (0000-0002-9577-330X); Shintaro Yagi (0000-0001-7465-5761); Kojiro Taura (0000-0003-4164-3988); Shinji Uemoto (0000-0003-0126-9346).

Author contributions: Ataka R designed and wrote the manuscript; Ito T performed operation and edited the manuscript; Masui T, Seo S, Ishii T, and Ogiso S performed operation; All authors discussed the results and contributed to the final manuscript.

Informed consent statement: The patient agreed to allow his case to be published including any relevant laboratory data and images.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE checklist, and the manuscript was prepared and reviewed according to the CARE checklist.

Abstract

BACKGROUND
Pancreaticobiliary maljunction (PBM) can be classified into two categories, PBM with congenital biliary dilatation (CBD) or PBM without biliary dilatation, and the management of PBM is often controversial. The treatment for PBM with CBD is prophylactic flow diversion surgery, and some authors have reported that the incidence of cancer after extrahepatic bile duct excision is less than 1%. A very rare case of intrahepatic cholangiocarcinoma 6 years after flow diversion surgery for PBM with CBD is reported.

CASE SUMMARY
A 30-year-old man was diagnosed as having PBM with CBD, Todani classification type IVA, because of abnormal liver enzyme profiles. He underwent flow diversion surgery and cholecystectomy, and the specimen showed adenocarcinoma foci, pT1, pStage IA. Five and a half years passed without any recurrence of bile duct cancer. However, 6 years after his operation, computed tomography showed a gradually growing nodule in the bile duct. Fluorodeoxyglucose positron emission tomography showed high uptake, and magnetic resonance imaging showed restricted diffusion signals. On double balloon enteroscopy, the nodule at the posterior bile duct-jejunum anastomosis was directly visualized, and its biopsy specimen showed adenocarcinoma. The patient underwent right lobectomy and biliary reconstruction. The pathological diagnosis was intraductal papillary neoplasm with high-grade intraepithelial neoplasia, pTis, pN0, pStage 0. The patient’s postoperative course was uneventful, and he has had no recurrence up to the present time.

CONCLUSION
This case suggests the necessity of careful observation after flow diversion surgery, especially when PBM with CBD is detected in adulthood.
INTRODUCTION

Pancreaticobiliary maljunction (PBM) is an uncommon congenital anomaly defined as junction of the pancreatic and bile ducts outside the duodenal wall, allowing reciprocal reflux of pancreatic juice and bile, which is carcinogenic. Thus, PBM is a high-risk factor for biliary tract cancer, and preventive surgery is necessary. Congenital biliary dilatation (CBD), one type of PBM, is usually treated with prophylactic flow diversion surgery, and the extent of intrahepatic and extrahepatic bile duct resection is often controversial[1,2]. A rare case of a young man who developed cholangiocarcinoma 6 years after flow diversion surgery for congenital biliary dilatation is described.

CASE PRESENTATION

A 30-year-old Japanese man was found to have liver dysfunction at a medical examination. He had no remarkable medical history, was not on any medications, and had no allergies to any food or drug. He visited a nearby hospital and was diagnosed as having PBM with CBD. His common bile duct showed cystic dilatation accompanied by intrahepatic bile duct dilatation, which was classified as Todani type IVA (Figure 1). In the same year, he underwent cholecystectomy and a flow diversion operation that consisted of excision of the extrahepatic bile duct, and biliary and Roux-en-Y reconstruction. According to the Union for International Cancer Control (UICC) 7th edition, the histopathological specimen showed adenocarcinoma foci, pT1, pNx, pStage IA. He did not have any adjuvant chemotherapy and five and a half years passed without any recurrence of biliary tract cancer.

MULTIDISCIPLINARY EXPERT CONSULTATION

However, six years after his operation, follow-up computed tomography (CT) showed a gradually growing nodule, about 10 mm in diameter, at the bile duct-jejunum anastomosis (Figure 2). Physical examination showed no abnormalities except for his previous operative scar. Laboratory tests were unremarkable, including liver and biliary enzyme profiles. Tumor markers were normal (carcinoembryonic antigen 0.8 ng/mL and carbohydrate 19-9 6.4 U/mL). Fluorodeoxyglucose positron emission tomography (FDG-PET) showed high FDG uptake, and magnetic resonance imaging showed restricted diffusion signals at the same nodular lesion. Double balloon enteroscopy showed the lesion directly. There were four holes anastomoses at the cholangiojejunostomy. A reddish and hemorrhagic tumor protruded from the posterior hole, and the other three holes were intact; the biopsy specimen showed adenocarcinoma (Figure 3).
Figure 1 3D-reconstruction of magnetic resonance cholangiopancreatography shows an abnormally dilated common bile duct (white star). Both right and left hepatic ducts also show intrahepatic dilatations (white arrows).

**FINAL DIAGNOSIS AND TREATMENT**

One month after percutaneous transhepatic portal embolization to prevent postoperative liver failure due to small remnant liver volume less than 30%, he underwent right lobectomy, biliary reconstruction, and regional lymph node dissection. At laparotomy, there were severe adhesions due to his previous operation. Right lobectomy was performed with dissection of the right hepatic artery, right portal vein, right hepatic vein, hilar bile ducts, and Roux-en-Y jejunum with cholangiojejunostomy. The remaining bile ducts in the hilar plate were three holes of B1, B2 plus B3, and B4. The biliary reconstruction was performed by new cholangiojejunostomy with a one-hole anastomosis. The Roux-en-Y reconstruction was also performed by a new jejunoojejunostomy. The histopathological diagnosis was intraductal papillary neoplasm of the bile duct with high-grade intraepithelial neoplasia. There were no other abnormal findings in other intrahepatic bile ducts, including the anterior and posterior branches, with a negative bile duct margin. The dissected lymph nodes showed no evidence of malignancy. According to the UICC 8th edition, the pTNM classification was pTis, pN0, pStage 0 (Figure 4).

**OUTCOME AND FOLLOW-UP**

The patient’s postoperative course was uneventful, and he was discharged on the 24th postoperative day. There has been no evidence of re-recurrence up to the present time.

**DISCUSSION**

PBM is a congenital anomaly defined as junction of the pancreatic and bile ducts outside the duodenal wall. Because of the abnormally located junction, the sphincter of Oddi does not work effectively. Reciprocal reflux of pancreatic juice and bile occurs, which introduces carcinogenic chemicals such as activated phospholipase A2 and secondary bile acids. These chemicals usually flow into the biliary tract because the hydropressure in the pancreatic duct is greater than that in the bile duct. The anomaly can also cause chronic cholangitis and chronic bacterbilia. As a result, patients with PBM have a higher risk of biliary tract cancer.

PBM can be divided into two categories: PBM with congenital biliary dilatation (CBD), which was previously called congenital choledochal cyst; or PBM without biliary dilatation (BD). Todani et al. classified this disease into five categories, and the Todani classification is now commonly used worldwide.

The essential management of PBM is prophylactic surgery to avoid carcinogenesis, and it should be performed immediately after the diagnosis of PBM. Since bile stasis in the dilated biliary tract is the most important factor for the development of
malignant changes in biliary epithelial cells[7], the treatment for PBM with CBD is prophylactic flow diversion surgery, and that for PBM without BD is prophylactic cholecystectomy. However, there is no consensus of opinion on whether intrahepatic dilated bile ducts should be resected for PBM with CBD, or whether extrahepatic non-dilated bile ducts should be resected for PBM without BD[8,9].

The present case showed a rare clinical course of PBM with CBD. Watanabe et al[9] reported that the incidence of cancer after extrahepatic bile duct excision is less than 1%. There seem to be two reasons for the carcinogenesis in this case. The first reason is that the flow diversion surgery left the dilated right hepatic duct in the hilar plate. In the first operation, the dilated left hepatic duct was removed, but the dilated right hepatic duct was used for cholangiojejunostomy. Since 30 years had passed before his diagnosis of CBD, there must have been some histological changes in the biliary epithelial cells, such as hyperplasia, metaplasia, and dysplasia. Damage and repair of the dilated biliary mucosa were likely to occur even after the first operation, resulting in carcinogenesis at the site of the cholangiojejunostomy. The second reason is that the reflux of intestinal juice at the cholangiojejunostomy probably played an important role in carcinogenesis. The stasis of bile and intestinal juice in the dilated biliary tract induces bacterial overgrowth and generation of unconjugated secondary bile acids[10]. The carcinogenic toxicity of secondary bile acids still remains unclear, but some authors report the following mechanism in mice and its relationship to humans. Secondary bile acids suppress the expression of chemokine ligand 16 (CXCL16), which recruits natural killer T cells, by liver sinusoidal endothelial cells. Then, the suppressed expression of CXCL16 weakens immunological defenses and leads to the development of malignancy and progression[11,12].

There have been 41 reported cases of biliary tract cancer after flow diversion surgery for PBM with CBD in the English literature from 1967 to 2016[7,13-41]. The characteristics of these patients are shown below (Table 1). Of the 41 cases reported, 35 reported details of the interval between age at flow diversion surgery and age at detection of biliary tract cancer. These 35 cases were divided into three groups by age (A, child group, 0-15; B, adolescent/young adult group, 16-30; and C, adult group, >30 years old), and the interval times are shown in the figure (Figure 5). There were significant differences between Group A and Group B (median 26.5 vs 4.0 years, \( P < 0.0001 \)), and between Group A and Group C (median 26.5 vs 8.5 years, \( P < 0.0001 \)), with no difference between Group B and Group C. These data mean that patients who undergo flow diversion surgery in adulthood can develop biliary tract cancer earlier than patients who undergo it in childhood. In adulthood, furthermore, interval time does not always depend on age at flow diversion surgery, and it is short, most often less than 10 years. This fact suggests that the damage to the remaining biliary epithelial cells due to carcinogenic chemicals is greater in adulthood than in childhood. In adulthood, the interval time may depend on the size of the dilated bile duct, on the extent of reflux, on the flow diversion procedures, or on lifestyle. The details remain unknown, and further similar cases need to be studied.

In the future, the current patient has a high probability of re-recurrence of cholangiocarcinoma. Although Tsuchida et al[42] reported that chemoprevention can be effective for PBM to prevent postoperative carcinogenesis, this is still controversial.
CONCLUSION

Follow-up throughout the life of a patient after flow diversion surgery is recommended\(^4\), but this is difficult in some cases. This case suggests the necessity of careful observation after flow diversion surgery, especially when PBM with CBD is detected in adulthood, and when cancer has already developed in the bile duct.
Table 1  Characteristics of the patients with biliary tract cancer after flow diversion surgery

| Variables                     | Number of Cases/years |
|-------------------------------|-----------------------|
| **Sex**                       |                       |
| Male                          | 8                     |
| Female                        | 24                    |
| NA                            | 9                     |
| **Todani classification**     |                       |
| I                             | 16                    |
| IVA                           | 16                    |
| NA                            | 9                     |
| **Age at flow diversion surgery**\(^1\) | 28.3 (0-68)          |
| NA                            | 8                     |
| **Age at detection of biliary tract cancer**\(^2\) | 42.3 (20-70)         |
| NA                            | 8                     |
| **Interval time**\(^3\)       |                       |
| NA                            | 12.6 (1-35)           |
| NA                            | 3                     |

\(^1\)Values are medians (range). NA: Not available.

Figure 4  Histological analysis of the tumor. A: Macroscopic findings; B: Hematoxylin and eosin (HE) staining, × 20; C: HE staining, ×400. Histological studies show papillary growth and fibrovascular cores in the macroscopically nodular area (yellow arrow), comprising high-grade atypical epithelial cells. There is no invasive carcinoma associated with the intraductal neoplasm.
Way analysis of variance and Bonferroni’s multiple comparison test. Data represent means and standard deviation. 
P < 0.0001, one-way analysis of variance and Bonferroni’s multiple comparison test.

Figure 5  The graph shows the relationship between age at diversion surgery and interval time. Data represent means and standard deviation.

REFERENCES

1. Kamisawa T, Ando H, Suyama M, Shimada M, Morine Y, Shimada H; Working Committee of Clinical Practice Guidelines for Pancreatobiliary Maljunction. Japanese Study Group on Pancreatobiliary Maljunction. Japanese clinical practice guidelines for pancreatobiliary maljunction. J Gastroenterol 2012; 47: 731-759 [PMID: 22722902 DOI: 10.1007/s00535-012-0611-2]

2. Kamisawa T, Ando H, Hamada Y, Fujii H, Koshinaga T, Urushihara N, Itoi T, Shimada H; Japanese Study Group on Pancreatobiliary Maljunction. Diagnostic criteria for pancreatobiliary maljunction 2013. J Hepatobiliary Pancreat Sci 2014; 21: 159-161 [PMID: 24307541 DOI: 10.1002/jbfs.57]

3. Kamisawa T, Takuma K, Anjiki H, Egawa N, Kuras, M, Honda G, Tsuruta K, Sasaki T. Pancreatobiliary maljunction. Clin Gastroenterol Hepatol 2009; 7: S84-S88 [PMID: 19896105 DOI: 10.1016/j.cgh.2009.08.024]

4. Hamada Y, Ando H, Kamisawa T, Itoi T, Urushihara N, Koshinaga T, Saito T, Fujii H, Morotomi Y. Diagnostic criteria for congenital biliary dilatation 2015. J Hepatobiliary Pancreat Sci 2016; 23: 342-346 [PMID: 26996969 DOI: 10.1016/j.jpbc.2016.04.003]

5. Todani T, Watanabe Y, Narusee M, Tabuchi K, Okajima K. Congenital bile duct cysts: Classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg 1977; 134: 263-269 [PMID: 8890444 DOI: 10.1016/0002-9610(77)90359-2]

6. Todani T. Congenital choledochal dilatation: classification, clinical features, and long-term results. J Hepatobiliary Pancreat Surg 1997; 4: 276-282 [DOI: 10.1007/BF02489025]

7. Fujii H, Yang Y, Tang R, Kunitomo I, Itakura J, Mogaki M, Matsuda M, Suda K, Nobukawa B, Matsumoto Y. Epithelial cell proliferation activity of the biliary ductal system with congenital biliary malformations. J Hepatobiliary Pancreat Surg 1999; 6: 294-302 [PMID: 10526066 DOI: 10.1007/s005340050121]

8. Kawasaki Y, Ds BC, Tabata M, Isaji S. Surgical treatment of type IV choledochal cysts. J Hepatobiliary Pancreat Surg 2009; 16: 684-687 [PMID: 19370303 DOI: 10.1007/s00534-009-0505-2]

9. Watanabe Y, Toki A, Todani T. Bile duct cancer developed after cyst excision for choledochal cyst. J Hepatobiliary Pancreat Surg 1999; 6: 207-212 [PMID: 10526053 DOI: 10.1007/s005340050108]

10. Reveille RM, Van Stegmann G, Everson GT. Increased secondary bile acids in a choledochal cyst. Possible role in biliary metaplasia and carcinoma. Gastroenterology 1990; 99: 525-527 [PMID: 21639382 DOI: 10.1016/0016-5085(90)91036-6]

11. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Kubota K, Wang XW, Trinchieri G, Greten TF. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018; 360: 29798856 [PMID: 29798856 DOI: 10.1126/science.aan5931]

12. Schramm C. Bile Acids, the Microbiome, Immunity, and Liver Tumors. N Engl J Med 2018; 379: 888-890 [PMID: 30157405 DOI: 10.1056/NEJMct1807106]

13. Thistlethwaite JR, Horwitz A. Choledochal cysts in adults: clinical management. Surgery 1984; 96: 656-663 [PMID: 6991285 DOI: 10.3109/10471743609109990]

14. Yoshikawa K, Yoshida K, Shirai Y, Sato N, Kashima Y, Coutinho DS, Koyama S, Muto T, Yamagiwa I, Iwafuchi M. A case of carcinoma arising in the intrapancreatic terminal choledochus 12 years after primary excision of a giant choledochal cyst. Am J Gastroenterol 1986; 81: 378-384 [PMID: 3706253 DOI: 10.1079/00024836-198606002-00012]
Tsuchida A, Itoi T. Carcinogenesis and chemoprevention of biliary tract cancer in pancreaticobiliary congenital choledochal cyst: a case report. 2016; Surg Case Rep: 19 [PMID: 26943695 DOI: 10.1007/s40724-016-0140-7]

Baik H, Park YH, Seo SH, An MS, Kim KH, Bae KB, Choi CS, Oh SH, Choi YK. Cholangiocarcinoma in type IV-A congenital choledochal cyst: report of a case. 2016; Ann Hepatobiliary Pancreat Surg 20: 354-358 [PMID: 23090140 DOI: 10.1016/j.ahbps.2015.09.003]

Ichikawa Y, Nagashima Y, Endo I. Intrahepatic cholangiocarcinoma arising 28 years after excision of a type IV-A congenital choledochal cysts. 2013; J Gastroenterol: 243-247 [PMID: 22989043 DOI: 10.1007/s00268-009-0184-2]

Kobayashi S, Asano T, Yamashiki M, Kenmochi T, Nakagohri T, Ochiai T. Risk of bile duct carcinogenesis after excision of extrahepatic bile ducts in pancreaticobiliary maljunction. 1999; 116: 939-944 [PMID: 10568195 DOI: 10.1007/s005350050701]

Fujisaki S, Akiyama T, Miyake H, Amano S, Tomita R, Fukazawa M, Yamagami H, Tsubaki K, Arakawa Y, Aleemuzzaman S, Nemioto N. A case of carcinoma associated with the remained intrapancreatic biliary tract 17 years after the primary excision of a congenital cholangiocarcinoma. 1999; 46: 1655-1659 [PMID: 10430315 DOI: 10.1016/S0016-5107(99)70411-6]

Jan YY, Chen HM, Chen MF. Malignancy in congenital biliary cysts. Hepatopancreatobiliary Surgery. 2000; 377-340 [PMID: 10791183]

Goto N, Yasada I, Uematsu T, Kanemura N, Takao S, Ando K, Katoh T, Osada S, Takao H, Saji S, Shimokawa K, Moriwaki H. Intrahepatic cholangiocarcinoma arising 10 years after the excision of congenital extrahepatic biliary dilatation. J Gastroenterol 2001; 36: 856-862 [PMID: 11777216 DOI: 10.1007/s005350170101]

Keiko M, Yasui K, Shimizu Y, Kodera Y, Hirai T, Morimoto T, Yamamuro Y, Katoh T. Carcinoma of the hepatic hilus developing 21 years after biliary diversion for choledochal cyst: a case report. Hepatopancreatobiliary Surgery 2002; 49: 1216-1220 [PMID: 12239908 DOI: 10.1039/b005651g]

Mahmut JY, Partensky C, Gouillat C, Baulieux J, Ducerf C, Kestens PJ, Boillot O, de la Roche E, Gigot JF. Cystic involvement of the roof of the main biliary convergence in adults with congenital bile duct cysts: a difficult surgical challenge. Surgery 2007; 141: 187-195 [PMID: 17263975 DOI: 10.1016/j.surg.2006.06.029]

Ono S, Sakai K, Kimura O, Iwai N. Development of bile duct cancer in a 26-year-old man after resection of infantile choledochal cyst. J Pediatr Surg 2008; 43: E17-E19 [PMID: 18558159 DOI: 10.1016/j.jpedsurg.2008.01.073]

Panalivelu C, Rangarajan M, Parhasaratharai R, Amar V, Senthilnathan P. Laparoscopic management of choledochal cysts: technique and outcomes--a retrospective study of 35 patients from a tertiary center. J Am Coll Surg 2008; 207: 839-846 [PMID: 19183529 DOI: 10.1016/j.jacssurg.2008.08.004]

Shimamura K, Kurusaki I, Sato D, Takano K, Yokoyama N, Sato Y, Hatakeyama N, Nakadaira K, Yagi M. Intrahepatic cholangiocarcinoma arising 34 years after excision of a type IV-A congenital cholangiocyst: report of a case. Surg Today 2009; 39: 247-251 [PMID: 19202836 DOI: 10.1007/s00595-008-8285-4]

Shah OJ, Shera AH, Zargar SA, Shah P, Robbani I, Dhar S, Khan AB. Choledochal cysts in children and adults with contrasting profiles: 11-year experience at a tertiary care center in Kashmir. World J Surg 2011; 33: 2403-2411 [PMID: 19701664 DOI: 10.1007/s00268-009-0184-2]

Nishiyama R, Shinoda M, Tanabe M, Asagi Y, Ueno A, Hibi T, Tateishi R, Fujisaki H, Kitago M, Itano O, Kawachi S, Aiura K, Tanimoto A, Sakamaoto M, Kitagawa Y. Intrahepatic cholangiocarcinoma arising 33 years after excision of a congenital cholangiocyst: report of a case. Int Surg 2011; 96: 320-325 [PMID: 22808614 DOI: 10.10738/c28.1]

Lee SE, Jang JY, Lee YJ, Choi DW, Lee WJ, Cho BH, Kim SW. Korean Pancreas Surgery Club. Choledochal cyst and associated malignant tumors in adults: a multicenter survey in South Korea. Arch Surg 2011; 146: 1178-1184 [PMID: 21960877 DOI: 10.1016/archsurg.2011.243]

Takeshita N, Ota T, Yamamoto M. Forty-year experience with flow-diversion surgery for patients with congenital choledochal cysts with pancreaticobiliary maljunction at a single institution. Ann Surg 2011; 354: 1050-1053 [PMID: 21659852 DOI: 10.1097/SLA.0b013e182243550f]

Ong J, Campbell W, Taylor MA. Metastatic cholangiocarcinoma following choledochal cyst excision: an unusual cause of abdominal pain in a 35-year-old female. Ulster Med J 2013; 82: 21-22 [PMID: 23620626]

Ohashi T, Wakai T, Kubota M, Matsuwa Y, Arai Y, Ohiyama T, Nakaya K, Okuyama N, Sakata J, Shirai Y, Ajoysa Y. Risk of subsequent bile duct malignancy in patients undergoing cyst excision for congenital choledochal cysts. J Gastroenterol Hepatol 2013; 28: 243-247 [PMID: 22989043 DOI: 10.1111/j.1440-1746.2012.07260.x]

Kumamoto T, Tanaka K, Takeda K, Nojiri K, Mori R, Taniguchi K, Matsuyma R, Ueda M, Sugita M, Ichikawa Y, Nagashima Y, Endo I. Intrahepatic cholangiocarcinoma arising 28 years after excision of a type IV-A congenital cholangiocyst: report of a case. Surg Today 2014; 44: 354-358 [PMID: 23909340 DOI: 10.1007/s00595-012-0387-2]

Baik H, Park YH, Seo SH, An MS, Kim KH, Bae KB, Choi CS, Oh SH, Choi YK. Cholangiocarcinoma in congenital cholangiocyst after cystoenterostomy: how a mistreated cholangiocyst can progress to malignancy. Ann Hepatobiliary Pancr Surg 2016; 20: 201-203 [PMID: 28261701 DOI: 10.14701/abbps.2016.20.4.201]

Yamada M, Ebata T, Sugawara G, Igami T, Mizuno T, Shingu Y, Nagino M. Hepatopancreatoduodenectomy for local recurrence of cholangiocarcinoma after excision of a type IV-A congenital choledochal cyst: a case report. Surg Case Rep 2016; 2: 19 [PMID: 26943695 DOI: 10.1186/s40792-016-0146-5]

Tsuchida A, Itoi T. Carcinogenesis and chemoprevention of biliary tract cancer in pancreaticobiliary dilatation.
maljunction. World J Gastrointest Oncol 2010; 2: 130-135 [PMID: 21160820 DOI: 10.4251/wjgo.v2.i3.130]
